Fred Alger Management, LLC Glycomimetics Inc Transaction History

Fred Alger Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 14, 2020	SELL	$2.06 - $3.76 $113,300 - $206,800	-55,000 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$1.83 - $5.41 $9,150 - $27,050	-5,000 Reduced 8.33%	55,000 $125,000
Q3 2019 Nov 14, 2019	BUY	$2.8 - $12.85 $56,000 - $257,000	20,000 Added 50.0%	60,000 $259,000
Q2 2019 Aug 14, 2019	BUY	$10.6 - $13.12 $424,000 - $524,800	40,000 New	40,000 $477,000
Q2 2018 Jul 19, 2018	SELL	$14.63 - $19.19 $102,410 - $134,330	-7,000 Closed	0 $0
Q1 2018 May 10, 2018	BUY	$16.06 - $25.35 $80,300 - $126,750	5,000 Added 250.0%	7,000 $114,000
Q4 2017 Feb 14, 2018	BUY	$10.51 - $17.22 $21,020 - $34,440	2,000	2,000 $34,000

17.8M

Ticker GLYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,423,900
Market Cap $16.8M
Description
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...

Get notified when there are updates to the investment portfolio of Fred Alger Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Fred Alger Management, LLC with notifications on news.